Notice: This company has been marked as potentially delisted and may not be actively trading. Leisure Acquisition (LACQ) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends LACQ vs. COYA, SGMT, PROC, DERM, BDRX, ORMP, VTYX, GALT, MIST, and IMUXShould you be buying Leisure Acquisition stock or one of its competitors? The main competitors of Leisure Acquisition include Coya Therapeutics (COYA), Sagimet Biosciences (SGMT), Procaps Group (PROC), Journey Medical (DERM), Biodexa Pharmaceuticals (BDRX), Oramed Pharmaceuticals (ORMP), Ventyx Biosciences (VTYX), Galectin Therapeutics (GALT), Milestone Pharmaceuticals (MIST), and Immunic (IMUX). Leisure Acquisition vs. Coya Therapeutics Sagimet Biosciences Procaps Group Journey Medical Biodexa Pharmaceuticals Oramed Pharmaceuticals Ventyx Biosciences Galectin Therapeutics Milestone Pharmaceuticals Immunic Coya Therapeutics (NASDAQ:COYA) and Leisure Acquisition (NASDAQ:LACQ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, community ranking, media sentiment, risk, profitability, earnings and institutional ownership. Which has more risk & volatility, COYA or LACQ? Coya Therapeutics has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, Leisure Acquisition has a beta of -0.3, meaning that its stock price is 130% less volatile than the S&P 500. Does the media refer more to COYA or LACQ? In the previous week, Coya Therapeutics had 5 more articles in the media than Leisure Acquisition. MarketBeat recorded 5 mentions for Coya Therapeutics and 0 mentions for Leisure Acquisition. Coya Therapeutics' average media sentiment score of 0.50 beat Leisure Acquisition's score of -1.38 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Coya Therapeutics Neutral Leisure Acquisition Negative Do analysts rate COYA or LACQ? Coya Therapeutics currently has a consensus target price of $16.25, suggesting a potential upside of 145.10%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Coya Therapeutics is more favorable than Leisure Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Leisure Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher earnings and valuation, COYA or LACQ? Leisure Acquisition has lower revenue, but higher earnings than Coya Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$9.55M11.59-$7.99M-$0.65-10.20Leisure AcquisitionN/AN/A$4.31MN/AN/A Does the MarketBeat Community believe in COYA or LACQ? Coya Therapeutics received 20 more outperform votes than Leisure Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformCoya TherapeuticsOutperform Votes2095.24% Underperform Votes14.76%Leisure AcquisitionN/AN/A Is COYA or LACQ more profitable? Leisure Acquisition's return on equity of 30.17% beat Coya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -31.63% -27.76% Leisure Acquisition N/A 30.17%6.14% Do insiders and institutionals hold more shares of COYA or LACQ? 39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 56.7% of Leisure Acquisition shares are held by institutional investors. 9.8% of Coya Therapeutics shares are held by company insiders. Comparatively, 39.6% of Leisure Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryCoya Therapeutics beats Leisure Acquisition on 8 of the 13 factors compared between the two stocks. Remove Ads Get Leisure Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for LACQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LACQ vs. The Competition Export to ExcelMetricLeisure AcquisitionPharmaceutical Preparations Industry SectorNASDAQ ExchangeMarket Cap$28.63M$6.93B$2.55B$8.08BDividend YieldN/A2.71%13.06%4.04%P/E RatioN/A6.1212.1219.00Price / SalesN/A226.084,932,637.57120.61Price / Cash20.0365.6721.4234.64Price / Book-24.216.653.354.26Net Income$4.31M$139.34M-$527.28M$247.00M Leisure Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LACQLeisure AcquisitionN/A$4.60-4.8%N/A+515.1%$28.63MN/A0.00N/ANegative NewsHigh Trading VolumeCOYACoya Therapeutics1.6476 of 5 stars$6.54-4.9%$16.25+148.5%-31.4%$109.26M$9.55M-10.066Upcoming EarningsAnalyst ForecastNews CoverageSGMTSagimet Biosciences2.823 of 5 stars$3.54-3.8%$23.00+549.7%-38.1%$108.59M$2M0.008Earnings ReportAnalyst ForecastNews CoveragePositive NewsPROCProcaps GroupN/A$0.95-40.3%N/A-70.8%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeDERMJourney Medical2.5218 of 5 stars$5.00-2.7%$9.67+93.3%+52.8%$104.45M$57.77M-5.3290Insider TradeShort Interest ↑News CoverageGap DownBDRXBiodexa Pharmaceuticals1.163 of 5 stars$2.85-6.6%N/AN/A$104.15M$83,000.000.0020Short Interest ↓News CoverageGap DownHigh Trading VolumeORMPOramed Pharmaceuticals1.8318 of 5 stars$2.51-2.3%N/A-10.9%$101.18M$1.34M22.8210VTYXVentyx Biosciences2.8824 of 5 stars$1.42-4.7%$10.00+604.2%-82.2%$101.01MN/A-0.6030GALTGalectin Therapeutics1.0495 of 5 stars$1.59-1.9%$11.00+591.8%-20.4%$99.79MN/A-2.189Gap DownMISTMilestone Pharmaceuticals2.4887 of 5 stars$1.86+1.1%$17.00+814.0%+17.5%$99.19M$1M-2.3030Short Interest ↑High Trading VolumeIMUXImmunic2.7691 of 5 stars$1.09-5.2%$12.67+1,062.1%-23.1%$98.19MN/A-0.8970Upcoming Earnings Remove Ads Related Companies and Tools Related Companies COYA Alternatives SGMT Alternatives PROC Alternatives DERM Alternatives BDRX Alternatives ORMP Alternatives VTYX Alternatives GALT Alternatives MIST Alternatives IMUX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LACQ) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredWarning: What they're not telling you about these recent selloffsIn light of massive recent selloffs... our senior analyst Dan Ferris has issued a new warning for the American...Stansberry Research | SponsoredSilent Raid on IRAs and 401(k)s Begins—Are You Next?Look around—everything feels oddly steady. Gas prices aren't skyrocketing. Banks aren't collapsing. The mar...Genesis Gold Group | SponsoredMagnificent 7 wipeout: What's next?A massive wave of volatility is sweeping the stock market... After the recent selloff, the "Magnificent Sev...Chaikin Analytics | SponsoredWarren Buffet Just Made a $334 Billion BetDebt is out of control. Inflation is creeping back. And a major market downturn could be right around the corn...Behind the Markets | SponsoredElon Refuses to Pay a DividendElon Musk refuses to pay a Tesla dividend. But thanks to a new investment breakthrough… You could start ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leisure Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leisure Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
